New October 11, 2025 – October 12, 2025 Nuclear Pharmacy CE Conference (12 CEUs)

Home New October 11, 2025 – October 12, 2025 Nuclear Pharmacy CE Conference (12 CEUs)

New October 11, 2025 – October 12, 2025 Nuclear Pharmacy CE Conference (12 CEUs)

$300.00

ACCREDITATION

iCARE Pharmacy Services, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This is an ACPE application-based* and knowledge-based activity. Participants may receive up to 12 hours of CPE credit by attending sessions and successfully completing the continuing pharmacy education (CPE) activity evaluation.

iCARE Pharmacy Services, Inc. is approved by the Florida Board of Pharmacy as a provider of continuing pharmacy education.

DISCLOSURES

Speakers have no relevant conflict of interests nor financial relationships.  All persons in a position to control the content of this activity have declared that no conflict of interest exists for this activity.

TARGET AUDIENCE

Pharmacists and Pharmacy Technicians of all practice backgrounds.

CANCELLATION POLICY
Participants must submit cancellations in writing. Participants will receive a credit for a future CPE program.

ZOOM WEBINAR INFORMATION
Participants may join via any electronic device. Be sure to have downloaded the ZOOM software in advance to avoid any delays. You will be able to see the speakers and their presentations. You will be able to respond to speaker learning assessments via the CHAT Feature and ask questions via the Q&A Feature.

Required Computer Hardware/Software

Please ensure your computer system meets the following Zoom minimum requirements:

  • 32-bit or 64-bit processor
  • Internet Browser (MAC and/or Windows) – Internet Explorer, Google Chrome, Firefox, Safari
  • Broadband internet connection: cable, high-speed DSL and any other medium that is internet accessible. Connect to hard wired Ethernet, secondary monitor, webcam, microphone
  • Monitor Screen Resolution – Need high resolution at least 320×480
  • Audio system – Computer speakers or headphones, laptop integrated speakers or desktop speakers
  • Media Viewing Requirements – Microsoft PowerPoint, Adobe reader
Add to Wishlist
Categories: , Tag:

Description

2025 Nuclear Pharmacy CE Conference (12 CEUs) (Brochure: Download)

 

SATURDAY, OCTOBER 11, 2025 

G = General Pharmacist CPE    T = Technician CPE

 

Emerging Role of Radiopharmaceuticals for Renal Cell Carcinoma

8:00am-9:30am P/T (1.5hrs CEUs)

Spencer Smith, PharmD, Clinical Nuclear Pharmacist Specialist, Michigan Medicine, University of MI

Upon completion of this activity, participants will be able to: Describe the pathophysiology, epidemiology, and treatment of renal cell carcinoma (RCC); Evaluate the results of recent

radiopharmaceutical clinical trials for RCC; Discuss potential applications of adiopharmaceuticals for RCC management.

UAN: 0675-0000-25-032-L01-P/T

 

Hosting a USP 825 Specific Inspection     

9:30am-11:00am P/T (1.5hrs CEUs)

Jessica Comstock, PharmD, BCNP, Vice President Pharmacy Quality and Regulatory, PharmaLogic Holdings

Upon completion of this activity, participants will be able to: Review key components of UPS 825 and how to respond to corresponding audit questions during an inspection; Identify differences in USP 825 and how to highlight them to inspectors who may not be as familiar with nuclear regulations; Discuss the art of hosting an inspection.

UAN: 0675-0000-25-033-L07-P/T

 

Enhancing Safety in Nuclear Pharmacies: A Review of Radiation Safety

11:15am-12:45pm P/T (1.5hrs CEUs)

Willie Regits, PhD, Senior Director, Supply Chain and Corporate Radiation Safety Officer, Clarity Pharmaceuticals

Upon completion of this activity, participants will be able to: Identify key radiation hazards and safety risks; Review best practices in radiation safety; Promote continuous education for new technologies and procedures.

UAN: 0675-0000-25-034-L99-P/T

 

Long-Lived Impurities in Isotopes: Impact on Waste Handling and Disposal Approaches

12:45pm-2:15pm P/T (1.5hrs CEUs)

Yasmine Saboui, MS, Director of Process Engineering, CMC Group, Abdera Therapeutics, Consultant - Targeted Design Solutions

Upon completion of this activity, participants will be able to: List isotopes with long-lived radioactive impurities: focus on Ac 225, Pb 212 and At-211; Discuss challenges to detection and handling; Explain the impact on site licensing requirements.

UAN: 0675-0000-25-035-L01-P/T

 

SUNDAY, OCTOBER 12, 2025

 

ClinicalTrials.gov Dissected: Behind the Public Listings

8:00am-9:30am P/T (1.5hrs CEUs)

Becca Segrest, PharmD, Area Manager – Nuclear & Precision Health, Cardinal Health

Upon completion of this activity, participants will be able to: Evaluate how the radiopharmaceutical research pipeline has changed over time: Number of trials by disease state, Diagnostic vs Therapeutic, •By isotope; Identify common and emerging diagnostic & therapeutic isotopes being studied; Discuss what early trends indicate about the future theranostic pairs; Discuss practical considerations for nuclear medicine department readiness and radiotherapy facilities.

UAN: 0675-0000-25-036-L01-P/T

 

Statistics in Nuclear Medicine       

9:30am-11:00am P/T (1.5hrs CEUs)

Jonathan Baldwin, PhD, Senior BioStatistician, TigerMed BDM

Upon completion of this activity, participants will be able to: List the problems associated with low count statistics for nuclear medicine; Determine the statistical variation encountered in a typical nuclear counting experiment (precision and chi square); Explain what “sufficiently rigorous to allow statistical confidence in the results” means when applied to assigning BUD; Define Sensitivity, Specificity, Accuracy, False Predictive Fraction, and Positive Predictive Value.

UAN: 0675-0000-25-037-L99-P/T

 

Evolving Scope of Nuclear Pharmacists in Radiopharmaceutical Manufacturing Part 211

11:15am-12:45pm P/T (1.5hrs CEUs)

Jenna DeJoris, PharmD, RPh, ANP, Assistant Production Manager, Nuclear Pharmacist, SpectronRx

Upon completion of this activity, participants will be able to: Define the role of nuclear CMOs and CDMOs in radiopharmaceutical development and production; Describe the nuclear pharmacist’s contributions to compliance, quality assurance, regulatory interpretation, and documentation management; Identify career-relevant skills and responsibilities of pharmacists in manufacturing compared to traditional pharmacy practice; Examine regulatory challenges in radiopharmaceutical manufacturing, with emphasis on 21CFR Part 211 versus 21 CFR Part 212.

UAN: 0675-0000-25-038-L03-P/T

 

Neuroendocrine Tumors: A 2025 Update for Nuclear Pharmacists

12:45pm-2:15pm P/T (1.5hrs CEUs)

Garcia Simon Clark, PharmD, MS, ANP, CCP, BCNP, Kindred Healthcare, Pharmacy Supervisor

Upon completion of this activity, participants will be able to: Describe the 2022 WHO classification and principal clinical subtypes of NETs; Compare and contrast Ga-68 DOTATE PET/CT and 123 I-MIBG SPECT/CT in terms of mechanism, biodistribution, sensitivity, and clinical useacross NET subtypes; Evaluate radiopharmaceutical and systemic therapies – 177 Lu-Dotate PRRT, 131 I-MIBG therapy, somatostatin analogs, targeted TKIs and their evidence base; Design an optimized diagnostic therapeutic algorithm for a given NET patient, integrating imaging choice, biomarker data, and guideline directed treatments.

UAN: 0675-0000-25-039-L01-P*

Related products